BGT 226 is a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin (PI3K/mTOR ) dual inhibitor which has shown to be effective with gefitinib in epidermal growth factor receptor (EGFR) inhibitor-sensitive non-small cell lung cancer (NSCLC) t
Molecular Weight:
650.6
CAS Number:
[1245537-68-1]
* VAT and and shipping costs not included. Errors and price changes excepted